S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:PRVBProvention Bio Stock Price, Forecast & News

$12.23
+0.43 (+3.64 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.56
Now: $12.23
$12.77
50-Day Range
$10.34
MA: $13.07
$17.00
52-Week Range
$4.72
Now: $12.23
$18.50
Volume783,372 shs
Average Volume795,472 shs
Market Capitalization$592.79 million
P/E RatioN/A
Dividend YieldN/A
Beta3.61
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.82 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRVB
CUSIPN/A
CIKN/A
Phone908-336-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-43,280,000.00

Miscellaneous

Employees13
Market Cap$592.79 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$12.23
+0.43 (+3.64 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRVB stock has increased by 35.7% and is now trading at $12.23.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Provention Bio?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Provention Bio
.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Provention Bio
.

How were Provention Bio's earnings last quarter?

Provention Bio Inc (NASDAQ:PRVB) issued its earnings results on Thursday, August, 6th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.17.
View Provention Bio's earnings history
.

What price target have analysts set for PRVB?

6 equities research analysts have issued 12 month target prices for Provention Bio's shares. Their forecasts range from $25.00 to $40.00. On average, they expect Provention Bio's share price to reach $29.00 in the next year. This suggests a possible upside of 137.1% from the stock's current price.
View analysts' price targets for Provention Bio
.

Has Provention Bio been receiving favorable news coverage?

Media coverage about PRVB stock has been trending very positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Provention Bio earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Provention Bio
.

Who are some of Provention Bio's key competitors?

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS).

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:
  • Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)
  • Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)
  • Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)
  • Mr. Cameron Gray Ph.D., MD & Director (Age 46)

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.20%), Swiss National Bank (0.18%), Russell Investments Group Ltd. (0.16%), Sigma Planning Corp (0.12%), SG Americas Securities LLC (0.12%) and Virtu Financial LLC (0.12%). Company insiders that own Provention Bio stock include Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt and Wayne Pisano.
View institutional ownership trends for Provention Bio
.

Which institutional investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Raymond James Financial Services Advisors Inc., and Virtus ETF Advisers LLC.
View insider buying and selling activity for Provention Bio
.

Which institutional investors are buying Provention Bio stock?

PRVB stock was acquired by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Swiss National Bank, Russell Investments Group Ltd., SG Americas Securities LLC, Virtu Financial LLC, New York State Common Retirement Fund, UBS Group AG, and Cambridge Investment Research Advisors Inc.. Company insiders that have bought Provention Bio stock in the last two years include Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, and Wayne Pisano.
View insider buying and selling activity for Provention Bio
.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $12.23.

How big of a company is Provention Bio?

Provention Bio has a market capitalization of $592.79 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.